Search Result

Results for "

HO-PEG2000-NH-Fmoc

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (3) Amino Acid Derivatives (1) Amylin Receptor (1) Biochemical Assay Reagents (3) Bombesin Receptor (1) Complement System (1) Drug Derivative (1) Drug Intermediate (1) Integrin (1) Isotope-Labeled Compounds (1) PROTACs (1) RXFP Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-41189

Fmoc-Val-Cit-PAB-PNP	ADC Linker	Cancer
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .

HY-P10392AF

fStAx-35R TFA	Wnt β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P11295

Fmoc-GGFG-PAB-PNP	ADC Linker	Cancer
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .

HY-174931A

*HO-PEG2000-NH-Fmoc*	Biochemical Assay Reagents	Others
HO-PEG2000-NH-Fmoc is a PEG derivative with an Fmoc protecting group and a hydroxyl (OH) reactive group. Fmoc is a commonly used amino protecting group that protects the amino group from unwanted reactions until it is removed for a specific coupling reaction.

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-W019682

Fmoc-FF	Biochemical Assay Reagents	Cancer
Fmoc-FF is a building block. Fmoc-FF-prepared hydrogels and nanogels selectively deliver Dexamethasone (HY-14648) to leukemia cells .

HY-P5045

Fmoc-Thr(GalNAc(Ac)3-β-D)-OH	Amino Acid Derivatives	Inflammation/Immunology Cancer
Fmoc-Thr(GalNAc(Ac)3-β-D)-OH inhibits cancer cell growth, through targeting intricate cancer-specific pathways while simultaneously strengthening immunologic response .

HY-169232

PCC16 chloride	PROTACs	Cancer
PCC16 chloride is a CRBN-based cp-PCC with an IC₅₀ value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .

HY-W1050525

Fmoc-Val-Ala-Gly	ADC Linker	Cancer
Fmoc-Val-Ala-Gly (compound 58a) is a cleavable ADC linker, can be conjugated to the antibody Trastuzumab (HY-P9907) to form an antibody-drug conjugate (ADC) .

HY-P11504

Fmoc-Lys-Gly-Dopa-OH	Biochemical Assay Reagents	Others
Fmoc-Lys-Gly-Dopa-OH is a tripeptide. Fmoc-Lys-Gly-Dopa-OH forms coacervates in aqueous solution via phase separation. Fmoc-Lys-Gly-Dopa-OH coacervates, with the assistance of Fe ³⁺, provide a viable material to engineer the surface of mammalian cells .

HY-P4613

Fmoc-D-allo-Thr-OH	Drug Derivative Drug Intermediate	Others
Fmoc-D-allo-Thr-OH is a derivative of D-allothreonine (HY-W001959), which is commonly used as a building block in solid-phase peptide synthesis (SPPS) .

HY-P11625

R9-13	RXFP Receptor	Cardiovascular Disease
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .

HY-P11830

UDA-6	Amylin Receptor	Metabolic Disease
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

*HO-PEG2000-NH-Fmoc*	Biochemical Assay Reagents
HO-PEG2000-NH-Fmoc is a PEG derivative with an Fmoc protecting group and a hydroxyl (OH) reactive group. Fmoc is a commonly used amino protecting group that protects the amino group from unwanted reactions until it is removed for a specific coupling reaction.

Cat. No.	Product Name	Target	Research Area

HY-P10392AF

fStAx-35R TFA	Wnt β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P11295

Fmoc-GGFG-PAB-PNP	ADC Linker	Cancer
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC) .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-W019682

Fmoc-FF	Biochemical Assay Reagents	Cancer
Fmoc-FF is a building block. Fmoc-FF-prepared hydrogels and nanogels selectively deliver Dexamethasone (HY-14648) to leukemia cells .

HY-P5037

Fmoc-Gly-Pro-Hyp-OH	Peptides	Others
Fmoc-Gly-Pro-Hyp-OH is a tripeptide that can be used in peptide synthesis .

HY-P5962

Fmoc-Gly-Pro-Hyp(OtBu)-OH TFA	Peptides	Others
Fmoc-Gly-Pro-Hyp(OtBu)-OH (TFA) is a tripeptide that can be used in peptide synthesis .

HY-P5045

Fmoc-Thr(GalNAc(Ac)3-β-D)-OH	Amino Acid Derivatives	Inflammation/Immunology Cancer
Fmoc-Thr(GalNAc(Ac)3-β-D)-OH inhibits cancer cell growth, through targeting intricate cancer-specific pathways while simultaneously strengthening immunologic response .

HY-169232

PCC16 chloride	PROTACs	Cancer
PCC16 chloride is a CRBN-based cp-PCC with an IC₅₀ value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .

HY-W1050525

Fmoc-Val-Ala-Gly	ADC Linker	Cancer
Fmoc-Val-Ala-Gly (compound 58a) is a cleavable ADC linker, can be conjugated to the antibody Trastuzumab (HY-P9907) to form an antibody-drug conjugate (ADC) .

HY-P5037A

Fmoc-Gly-Pro-Hyp-OH TFA	Peptides	Others
Fmoc-Gly-Pro-Hyp-OH TFA is a tripeptide that can be used in peptide synthesis .

HY-P11504

Fmoc-Lys-Gly-Dopa-OH	Biochemical Assay Reagents	Others
Fmoc-Lys-Gly-Dopa-OH is a tripeptide. Fmoc-Lys-Gly-Dopa-OH forms coacervates in aqueous solution via phase separation. Fmoc-Lys-Gly-Dopa-OH coacervates, with the assistance of Fe ³⁺, provide a viable material to engineer the surface of mammalian cells .

HY-P4613

Fmoc-D-allo-Thr-OH	Drug Derivative Drug Intermediate	Others
Fmoc-D-allo-Thr-OH is a derivative of D-allothreonine (HY-W001959), which is commonly used as a building block in solid-phase peptide synthesis (SPPS) .

HY-P11625

R9-13	RXFP Receptor	Cardiovascular Disease
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .

HY-P11830

UDA-6	Amylin Receptor	Metabolic Disease
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name	Chemical Structure

HY-P3252AS

Pegcetacoplan-13C3,15N TFA
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Pegcetacoplan-13C3,15N TFA

Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy